πππThe Global Weight Management Market size is calculated at USD 160.15 billion in 2024 and is expected to reach USD 328.24 billion by 2032, growing at a CAGR of 8.3% from 2024 to 2032.
Roundhill Investment has just launched $Roundhill GLP-1 & Weight Loss ETF(OZEM)$ on May 21 to capture this growing market. OZEM is the world 's first GLP-1 and Weight Loss ETF.
GLP-1 is a revolutionary treatment which reduces food intake, appetite and hunger and promotes fullness and satiety with the ultimate result of promoting weight loss.
Groundbreaking GLP-1 treatments such as Wegovy by Novo-Nordisk and Ozempic by Eli Lilly are leading medical advancement in weight management.
The Top 10 holdings include $Eli Lilly(LLY)$ at 21% weightage, $Novo-Nordisk A/S(NVO)$ at 20% followed by Zealand Pharma A/S, Amgen Inc, Chugai Pharmaceutical, Innovent Biologics, Terns Pharmaceuticals, Altimmune Inc, Viking Therapeutics and Structure Therapeutics.
Top 10 holdings weightage is 71%. Total number of holdings is 28. The expense ratio is 0.59%. Distributions will be paid annually.
Performance wise OZEM ETF is down 0.7% today and in the past 5 days it is down 2.4%.
I like $Roundhill GLP-1 & Weight Loss ETF(OZEM)$ as it is great value for money. At the last closing price of USD 24.80 per share, it is a lot cheaper than investing in $Eli Lilly(LLY)$ which is USD 811.53 per share.
Both Eli Lilly and Novo Nordisk are market leaders in the weight loss drugs. However there are other companies trying to get a slice of the market too.
Zealand Pharma A/S is a Danish biotechnology research company which designs and develops peptide based medicines, mainly focusing on metabolic diseases like diabetes and obesity.
$Amgen(AMGN)$ discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting edge of innovation, using technology and human genetic data to push beyond what is known today.
Chugai Pharmaceutical is a Japanese company founded in 1925. It entered into a strategic alliance with Roche in October 2002, becoming a member of the Roche Group.
$Viking Therapeutics(VKTX)$ provided details of a phase 1 study of a weight loss drug that showed patients in the study who received tablets of the drug codenamed VK2735 achieved noticeable weight loss in March this year. Viking Therapeutics stock has since shot up over 200% year todate.
The World Health Organisation said that Obesity has reached epidemic proportions globally with at least 2.8 million people dying each year as a result of being overweight or obese. So weight loss drugs are a game changer. Goldman Sachs Research forecasts that obesity treatment market could expand by more than 16 times its current size to reach USD 100 billion by 2030.
So I believe the time is ripe to invest in OZEM ETF to capture this growing market.
@Daily_Discussion @TigerStars @MillionaireTiger @Tiger_comments @CaptainTiger
Comments